A group of interdisciplinary researchers from universities and medical colleges in Lagos, Nigeria, recently published a study in the Italian Journal of Pediatrics that has significant public health implications on treating children with sickle cell anemia (SCA) in the developing world. The study, “…
News
A recently published study in the Journal of Clinical Investigation identified an association between worsening intravascular hemolysis (rupture or destruction of red blood cells) and the rapid clinical deterioration seen during adult transition in Sickle cell disease (SCD). The study, “Nonhematopoietic Nrf2 dominantly…
Sickle cell anemia (SCA), one of the most common hemoglobinopathies, is caused by a mutation in the β-globin gene. In a new research study, the hemorheological and hematological parameters in men suffering from SCA and priapism — a persistent and potentially painful state of penile erection — were investigated.
A study performed by researchers at Baskent University, in Ankara, Turkey, found that mutations in certain genes play a role in the deposition of iron in the liver of patients with sickle cell (SC) disease. Findings, presented in the study “Effect of Hereditary Hemochromatosis Gene (HFE)…
Acetylon Pharmaceuticals recently published the outcomes of its preclinical data concerning the mechanism of action of its selective inhibition based treatment of sickle cell (SC) disease/beta-thalassemia (BT). These findings, “Chemical Inhibition of Histone Deacetylases 1 and 2 Induces Fetal Hemoglobin through Activation of GATA2,” were published in…
Recent Posts
- New reimbursement deal in Germany expands access to Casgevy for SCD
- New York study finds regional gaps in sickle cell disease hospitalizations
- When a sickle cell pain crisis interrupts a stretch of good health, part 1
- Scientists discover how stressed red blood cells make hemoglobin
- How my sickle cell disease advocacy has evolved over time
- New study links sickle cell anemia to lower ovarian reserve in women
- $3M Breakthrough Prize honors duo whose work changed SCD treatment
- Etavopivat Phase 3 results support potential approval in sickle cell disease
- New diagnoses result in new grief and a new relationship with my body
- Study finds lower treatment use among SCD patients in sub-Saharan Africa